Delcath Systems (NASDAQ:DCTH) Price Target Raised to $21.00

Delcath Systems (NASDAQ:DCTH) had its price objective lifted by stock analysts at Craig Hallum from $18.00 to $21.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Craig Hallum’s price target suggests a potential upside of 50.12% from the company’s current price.

DCTH has been the subject of several other reports. Canaccord Genuity Group reaffirmed a “buy” rating and set a $21.00 price objective on shares of Delcath Systems in a research note on Friday, October 18th. HC Wainwright restated a “buy” rating and set a $22.00 price target on shares of Delcath Systems in a research note on Tuesday. Stephens reiterated a “buy” rating on shares of Delcath Systems in a research report on Friday, October 18th. Finally, StockNews.com raised shares of Delcath Systems from a “sell” rating to a “hold” rating in a research note on Friday, October 25th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Delcath Systems currently has an average rating of “Moderate Buy” and an average price target of $22.25.

Delcath Systems Price Performance

Shares of NASDAQ:DCTH traded up $0.32 on Friday, reaching $13.99. The company’s stock had a trading volume of 304,452 shares, compared to its average volume of 471,266. Delcath Systems has a 52-week low of $3.70 and a 52-week high of $14.41. The stock has a market capitalization of $447.23 million, a P/E ratio of -10.40 and a beta of 0.87. The stock’s 50-day moving average is $11.42 and its two-hundred day moving average is $9.88.

Institutional Trading of Delcath Systems

Several hedge funds have recently modified their holdings of the business. Marshall Wace LLP raised its position in Delcath Systems by 7.0% in the second quarter. Marshall Wace LLP now owns 92,731 shares of the company’s stock worth $776,000 after acquiring an additional 6,066 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Delcath Systems by 3.0% during the 3rd quarter. Geode Capital Management LLC now owns 251,895 shares of the company’s stock worth $2,275,000 after purchasing an additional 7,298 shares during the period. State Street Corp increased its holdings in shares of Delcath Systems by 12.4% in the 3rd quarter. State Street Corp now owns 85,457 shares of the company’s stock valued at $772,000 after purchasing an additional 9,400 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Delcath Systems in the third quarter valued at about $102,000. Finally, Barclays PLC purchased a new stake in Delcath Systems during the third quarter worth about $104,000. 61.12% of the stock is owned by institutional investors and hedge funds.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.